✦ LIBER ✦

Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies

✍ Scribed by Casey B. Williams; Suzanne D. Day; Michael D. Reed; Edward A. Copelan; Thomas Bechtel; Helen L. Leather; John R. Wingard; Brian L. Abbott; Sunil Abhyankar; Joseph P. McGuirk

Book ID: 116277871
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 128 KB
Volume: 10
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2004.05.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I dose escalation study of high-

A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies

✍ Demirer, T; lhan, O; Mandel, N M; Arat, M; Günel, N; Çelebi, H; Üstün, C; Akan, 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 70 KB

318: Busulfan, Fludarabine and Total Bod

318: Busulfan, Fludarabine and Total Body Irradiation Followed by Allogeneic Peripheral Blood Stem Cell Transplantation is an Effective Treatment for Hematologic Malignancies with Acceptable Toxicity in a Higher-Risk Population

✍ G. Meyers; A. Dunn; T. Kovacsovics; W. Fleming; E. Epner; B. Hayes-Lattin; M. Ma 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 52 KB

High-dose therapy and autologous periphe

High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients

✍ Massimo Martino; Giuseppe Console; Giuseppe Irrera; Giulia Praticò; Caterina Ste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 2 views

## Abstract The recent development of reduced intensity conditioning and allotransplantation (RICT) has opened a new way to assure engraftment of donor cells while reducing early transplant‐related mortality. We evaluated the combination of high‐dose therapy and autologous peripheral blood stem cel